Corning announced its new Corning Epic Pharmacology service for drug discovery. The service uses Corning’s holistic assay approach to drug discovery and pathway biology to provide high-value cellular profiling in native cellular systems.
The Corning Epic Pharmacology service is a key new offering from Corning’s portfolio of Epic Discovery Services, and helps reveal hidden compound activities, unforeseen pathway activities, and can identify both novel pharmacology and off-target effects for high-value compounds. Leveraging Corning’s Epic label-free technology, the Epic Pharmacology service provides more biologically relevant data to enhance customers’ decision-making in compound prioritization, helping them drive increased discovery productivity.
“Today’s drug discovery market is challenged not only with bringing drugs to market faster, but doing so more efficiently and effectively while remaining continually vigilant about quality,” said Keith R. Olson, Ph.D., business director, Advanced Life Sciences, Corning. “Our new Corning Epic Pharmacology service will provide our customers worldwide with significant knowledge and expertise needed to address and overcome these current challenges. Our approach is customized to each client’s need, providing a cellular profiling panel for drug activity in a range of primary and immortalized cells that more accurately reflects how drugs behave in vivo.”
Source: Corning Inc.